ClinicalTrials.gov
Cure8 trial brief
Treatment of UC With Novel Therapeutics
Research and clinical trials
Mesalamine
Aminosalicylates
Phase 2 clinical trial
Adult patients
Clinicians
Researchers
Patients On Biologics
Why This Matters
This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic treatment option for patients on mesalamine who still have active disease.
Who Should Pay Attention
Adults with mild active ulcerative colitis, clinicians treating UC, and researchers interested in new oral therapies, H2S-related biomarkers, or microbiome-linked approaches.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 2
Enrollment20 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This is a phase 2, randomized crossover trial (NCT06420375) testing an investigational oral drug called BRS201 for adults with mild active ulcerative colitis.
The study lasts 12 weeks with two 4-week treatment periods (active drug and placebo in randomized order) and includes blood, stool, and urine testing; the primary outcome is reduction of H2S metabolites in plasma after 4 weeks. The trial allows stable mesalamine or sulfasalazine but excludes use of many immunomodulators and biologics within recent weeks.
The study is recruiting at Brigham and Women's Hospital.
Keep In Mind
This is an early-phase (phase 2) small crossover trial (planned N=20) focused on a biomarker endpoint (plasma H2S metabolites) rather than clinical remission. The study population excludes patients on most immunosuppressants and biologics, so results may not apply to patients with moderate–severe disease or those on combination therapy.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorBrigham and Women's Hospital
Trial IDNCT06420375
Study typeInterventional
Trial phasePhase 2
Enrollment20 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedJul 21, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Palmitoylethanolamide in Ulcerative Colitis
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
Understanding role of microbiota in Crohn's disease, ulcerative colitis
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...